WO1993022433A3 - Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament - Google Patents

Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament Download PDF

Info

Publication number
WO1993022433A3
WO1993022433A3 PCT/DE1993/000374 DE9300374W WO9322433A3 WO 1993022433 A3 WO1993022433 A3 WO 1993022433A3 DE 9300374 W DE9300374 W DE 9300374W WO 9322433 A3 WO9322433 A3 WO 9322433A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
viruses
animals
human beings
retro
Prior art date
Application number
PCT/DE1993/000374
Other languages
German (de)
English (en)
Other versions
WO1993022433A2 (fr
Inventor
Frank Andreas Harald Meyer
Original Assignee
Frank Andreas Harald Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frank Andreas Harald Meyer filed Critical Frank Andreas Harald Meyer
Priority to EP93911729A priority Critical patent/EP0677103A1/fr
Publication of WO1993022433A2 publication Critical patent/WO1993022433A2/fr
Publication of WO1993022433A3 publication Critical patent/WO1993022433A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1276RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae

Abstract

Dans l'organisme de l'homme et dans celui des animaux, les maladies sont induites entre autres, par des virus. De nombreux rétrovirus sont porteurs d'oncogènes. Pour lutter contre les rétrovirus, on essayait jusqu'à maintenant d'intervenir sur des rétrovirus accomplis. Les inconvénients de la thérapie connue résident dans le fait que l'on ne peut empêcher l'apparition de diverses formes d'effets secondaires qui sont lourds à gérer pour le patient traité et que s'il est avéré que l'on peut retarder l'évolution de nombreuses maladies, on n'arrive pas pour autant à les enrayer. Ce nouveau médicament est adapté notamment pour bloquer la prolifération de virus et pour bloquer les carcinogènes. Ce médicament contient des enveloppes de virus qui s'arriment aux récepteurs des cellules souches connues. Ce médicament comprend des cellules prélevées sur l'organisme, qui ont été traités avec des antivirus. Ce médicament comprend des cellules prélevées sur l'organisme et traitées avec les liposomes glucolysés appropriés. L'utilisation de ce médicament ne génère qu'un très petit nombre d'effets secondaires pénibles pour le patient traité et permet de guérir des maladies.
PCT/DE1993/000374 1992-04-28 1993-04-28 Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament WO1993022433A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP93911729A EP0677103A1 (fr) 1992-04-28 1993-04-28 Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ATPCT/EP92/00923 1992-04-28
EP9200923 1992-04-28
DE4238879 1992-11-19
DEP4238879.1 1992-11-19

Publications (2)

Publication Number Publication Date
WO1993022433A2 WO1993022433A2 (fr) 1993-11-11
WO1993022433A3 true WO1993022433A3 (fr) 1994-07-07

Family

ID=25920549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1993/000374 WO1993022433A2 (fr) 1992-04-28 1993-04-28 Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament

Country Status (2)

Country Link
AU (1) AU4259193A (fr)
WO (1) WO1993022433A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650370A4 (fr) * 1992-06-08 1995-11-22 Univ California Procedes et compositions permettant de cibler des tissus specifiques.
DE19503082A1 (de) * 1995-02-01 1996-08-08 Univ Ludwigs Albert Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240332A2 (fr) * 1986-04-02 1987-10-07 Pioneer Hi-Bred International, Inc. Plantes résistantes aux virus comportant l'ARN anti-sens
EP0278667A2 (fr) * 1987-02-09 1988-08-17 Mycogen Plant Science, Inc. Virus d'ARN hybride
WO1990005538A1 (fr) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Capsides de parvovirus
EP0387775A1 (fr) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Unité génétique pour inhiber la fonction d'ARN
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992006180A1 (fr) * 1990-10-01 1992-04-16 University Of Connecticut Ciblage de virus et de cellules pour leur inclusion selective dans des cellules

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240332A2 (fr) * 1986-04-02 1987-10-07 Pioneer Hi-Bred International, Inc. Plantes résistantes aux virus comportant l'ARN anti-sens
EP0278667A2 (fr) * 1987-02-09 1988-08-17 Mycogen Plant Science, Inc. Virus d'ARN hybride
WO1990005538A1 (fr) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Capsides de parvovirus
EP0387775A1 (fr) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Unité génétique pour inhiber la fonction d'ARN
WO1990012087A1 (fr) * 1989-04-05 1990-10-18 Novacell Corporation Particule virale infectieuse ciblee a replication defectueuse
WO1992005266A2 (fr) * 1990-09-21 1992-04-02 Viagene, Inc. Cellules d'encapsidation
WO1992006180A1 (fr) * 1990-10-01 1992-04-16 University Of Connecticut Ciblage de virus et de cellules pour leur inclusion selective dans des cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GAREIS, M. ET AL.: "Homologous recombination of exogenous DNA fragments with genomic DNA in somatic cells of mice", CELLULAR AND MOLECULAR BIOLOGY, vol. 37, no. 2, 1991, pages 191 - 203, XP000406056 *

Also Published As

Publication number Publication date
WO1993022433A2 (fr) 1993-11-11
AU4259193A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
AU8335291A (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals
CA2214503A1 (fr) Methode de traitement de tumeurs
IL105366A0 (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ZA95679B (en) Products containing G-CSF and TNF binding protein
DE3650505T2 (de) AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung.
WO1993022433A3 (fr) Medicament permettant de traiter l'homme, les animaux et les plantes par therapie genetique, dans le but notamment de bloquer la proliferation de virus et les carcinogenes et procede de fabrication dudit medicament
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
GB8917323D0 (en) Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
US5547672A (en) Accelerated wound healing
GR3032224T3 (en) Therapeutic agent for threatened abortion.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
HK1042239A1 (en) Bupropion to treat viral diseases.
EP0668771A4 (fr) Traitement des maladies autoimmunes par induction d'une tolerance des cellules, des tissus et des organes.
RU94006478A (ru) Способ световой терапии
Aliev et al. The possibility of the use of interferon in the treatment of alcoholism.
RU92011168A (ru) Препарат для лечения гинекологических заболеваний
RU2002131990A (ru) Способ лечения пострадавших с черепно-мозговой травмой в ранний посттравматический период
ZA938915B (en) Treatment of viral infections by conjunctive therapy with acyclovir-like compounds and a 2'-vynyl substituted nucleoside analog
FARSHATOV The role of radioprotectors in the effectiveness of the treatment of combined radiation injuries(Vliianie radioproektorov na effektivnost' lecheniia kombinirovannykh radiatsionnykh porazhenii(Obzor literatury))
RU94043033A (ru) Способ коррекции и модуляции иммуногомеостаза при заболеваниях внутренних органов и нервной системы
MD197G2 (ro) Preparat şi procedeu de tratare a hipogalactiei
Juca et al. Antimicrobial therapy with cefoxitin sodium in vascular surgery and angiology: Clinical and laboratorial survey.
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
RU92011195A (ru) Способ уменьшения дозы химиопрепаратов, используемых для лечения инфекционных заболеваний при одновременном повышении их терапевтической эффективности

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CZ DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CZ DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: CA

WWE Wipo information: entry into national phase

Ref document number: 1993911729

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993911729

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1993911729

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993911729

Country of ref document: EP